UNDERSTANDING PROSTAGLANDIN METABOLITES AND PLATELET-ACTIVATING-FACTOR IN THE PATHOPHYSIOLOGY AND TREATMENT OF THE ANTIPHOSPHOLIPID SYNDROME

Prostaglandin metabolites, including thromboxane, prostacyclin, and platelet-activating factor, may participate as intermediaries in the pathophysiology of the primary antiphospholipid syndrome (PAPS). In order to determine safe and effective therapies for patients with PAPS, we must improve our knowledge base and specific understanding of the mechanisms that link circulating antiphospholipid antibodies to decidual vasculopathy and fetal death. A review of current research is presented along with an evaluation of medical therapy whose rationale for use is consistent with current evidence.